ALKBH5 and glioblastoma: Furthermore, we found that deletion of ALKBH5 enhanced the anti-PD-1 therapeutic effect, and the combination of anti-PD-1 antibody and IXO1, an ALKBH5 inhibitor, increased the survival benefits of GBM-bearing mice.